LHC Group - LHCG Stock Forecast, Price & News

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for LHC Group in the last year. There are currently 8 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" LHCG shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in LHCG, but not buy additional shares or sell existing shares.
View LHCG analyst ratings or view top-rated stocks.

8 Wall Street research analysts have issued 12 month target prices for LHC Group's shares. Their LHCG share price forecasts range from $170.00 to $185.00. On average, they anticipate the company's share price to reach $172.50 in the next year. This suggests a possible upside of 9.9% from the stock's current price.
View analysts price targets for LHCG or view top-rated stocks among Wall Street analysts.

LHC Group's stock was trading at $161.69 at the beginning of the year. Since then, LHCG stock has decreased by 2.9% and is now trading at $156.94.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 22nd 2023.
View our LHCG earnings forecast.

LHC Group, Inc. (NASDAQ:LHCG) posted its earnings results on Wednesday, November, 2nd. The health services provider reported $1.06 earnings per share for the quarter, missing analysts' consensus estimates of $1.37 by $0.31. The health services provider earned $576.91 million during the quarter, compared to analyst estimates of $616.65 million. LHC Group had a net margin of 2.73% and a trailing twelve-month return on equity of 8.13%.

524 employees have rated LHC Group Chief Executive Officer Keith G. Myers on Glassdoor.com. Keith G. Myers has an approval rating of 87% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other LHC Group investors own include Verizon Communications (VZ), NVIDIA (NVDA), Home Depot (HD), Cisco Systems (CSCO), Visa (V), CVS Health (CVS), Johnson & Johnson (JNJ), Alibaba Group (BABA), Chevron (CVX) and Intel (INTC).

LHC Group trades on the NASDAQ under the ticker symbol "LHCG."

LHC Group's stock is owned by many different retail and institutional investors. Top institutional investors include Versor Investments LP (0.95%), Syquant Capital Sas (0.39%), Calamos Advisors LLC (0.32%), Ziegler Capital Management LLC (0.15%), New York State Common Retirement Fund (0.09%) and Bridge City Capital LLC (0.05%). Insiders that own company stock include Nicholas Gachassin III, Ronald T Nixon and W Earl Reed III.
View institutional ownership trends.

Shares of LHCG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of LHCG stock can currently be purchased for approximately $156.94.

LHC Group (NASDAQ:LHCG) has a market capitalization of $4.87 billion and generates $2.22 billion in revenue each year. The health services provider earns $115.73 million in net income (profit) each year or $2.05 on an earnings per share basis.

The company employs 30,000 workers across the globe.

LHC Group's mailing address is 901 HUGH WALLIS ROAD SOUTH, LAFAYETTE LA, 70508. The official website for the company is www.lhcgroup.com. The health services provider can be reached via phone at (337) 233-1307, via email at eric.elliott@lhcgroup.com, or via fax at 337-235-8037.